NervGen Pharma (NGEN)
Develops NVG-291 for spinal-cord injury.
$2.00
vs last close−0.06 (−3.15%)
In millions of USD, except per-share figures · converted from CAD at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 3 | 4 | 4 | 5 | 5 | 4 | 5 | 4 | 8 | 5 | 9 | |
| Research & development | 0 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 5 | 3 | 6 |
| Selling, general & administrative | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 1 | 4 | 2 | 3 |
| Operating income | −2 | −3 | −4 | — | −5 | −5 | −4 | −5 | −4 | −8 | −5 | −9 |
| 0 | — | 2 | −1 | 1 | −1 | 1 | −2 | 1 | −14 | 4 | −12 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 3 | −2 | 1 | — | 1 | — | 2 | −1 | −13 | −4 | 0 |
| Income before tax | −2 | −6 | −2 | −6 | −4 | −6 | −3 | −6 | −3 | −22 | −1 | −21 |
| Net income from continuing operations | −2 | −6 | −2 | −6 | −4 | −6 | −3 | −6 | −3 | −22 | −1 | −21 |
| Net income | −2 | −6 | −2 | −6 | −4 | −6 | −3 | −6 | −3 | −22 | −1 | −21 |
| EPS, basic | −$0.04 | −$0.11 | −$0.03 | −$0.08 | −$0.05 | −$0.09 | −$0.04 | −$0.09 | −$0.04 | −$0.31 | −$0.02 | −$0.23 |
| EPS, diluted | −$0.04 | −$0.11 | −$0.03 | −$0.08 | −$0.05 | −$0.09 | −$0.04 | −$0.09 | −$0.04 | −$0.31 | −$0.02 | −$0.23 |
| Weighted average shares, basic | 59 | 60 | 60 | 70 | 70 | 70 | 71 | 72 | 73 | 72 | 80 | 92 |
| Weighted average shares, diluted | 59 | 60 | 60 | 70 | 70 | 70 | 71 | 72 | 73 | 72 | 80 | 92 |
| EBITDA | −2 | −6 | −2 | −6 | −4 | −6 | −3 | −6 | −3 | 5 | −1 | −9 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −6 | — | — | −4 | −6 | −3 | −6 | −3 | 5 | −1 | −9 |